A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer

SIMPLE SUMMARY: Metastatic prostate cancer has traditionally been treated with a combination of hormonal and chemotherapy regimens. With the recent FDA approval of targeted radionuclide therapeutics, there is now a new class of therapy that is routinely available to patients and clinicians. This rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Parent, Ephraim E., Kase, Adam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454920/
https://www.ncbi.nlm.nih.gov/pubmed/36077820
http://dx.doi.org/10.3390/cancers14174276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9454920/
https://www.ncbi.nlm.nih.gov/pubmed/36077820
http://dx.doi.org/10.3390/cancers14174276

Ejemplares similares